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Abstract: Stimulation of the dopamine D1 receptor is reported to cause the phosphorylation 
of DARPP-32 at the thre34 position and activates the protein. If intracellular Ca
2+
 is 
increased, such as after activation of the glutamate NMDA receptor, calcineurin activity 
increases and the phosphates will be removed. This balance of phosphorylation control 
suggests that a D1 receptor agonist and a NMDA glutamate receptor antagonist should have 
additive or synergistic actions to increase activated DARPP-32 and consequent behavioral 
effects. This hypothesis was tested in a volitional consumption of ethanol model: the 
selectively bred Myers’ high ethanol preferring (mHEP) rat. A 3-day baseline period was 
followed by 3-days of twice daily injections of drug(s) or vehicle(s) and then a 3-day  
post-treatment period. Vehicle, the D1 agonist SKF 38393, the non-competitive NMDA 
receptor antagonist memantine, or their combination were injected 2 h before and after 
lights out. The combination of 5.0 mg/kg SKF 38393 with either 3.0 or 10 mg/kg 
memantine did not produce an additive or synergistic effect. For example, 5.0 mg/kg SKF 
reduced consumption of ethanol by 27.3% and 10 mg/kg memantine by 39.8%. When 
combined, consumption declined by 48.2% and the proportion of ethanol solution to total 
fluids consumed declined by 17%. However, the consumption of food also declined by 
36.6%. The latter result indicates that this dose combination had a non-specific effect. The 
combination of SKF 38393 with (+)-MK-801, another NMDA receptor antagonist, also 
failed to show an additive effect. The lack of additivity and specificity suggests that the 
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hypothesis may not be correct for this in vivo model.  The interaction of these different 
receptor systems with intraneuronal signaling and behaviors needs to be studied further. 
Keywords: glutamate receptors; consumatory behaviors; DARPP-32 
 
1. Introduction 
Ethanol interacts with the functioning of many different neurotransmitter systems. These 
interactions include increased dopaminergic impulse flow likely through an opiate receptor mediated 
system [1], potentiation of gamma-aminobutyric acid (GABA) at the GABAA receptor, inhibition of 
excitatory glutamate (NMDA) receptors [2,3], release of angiotensin II [4] and an agonist-like 
interaction with adenosine receptors [5,6]. The search for drugs that will reduce the desire to consume 
alcohol similarly involves modification of the function of these neurotransmitter-receptor systems. One 
such example is the use of opiate receptor antagonists such as naltrexone to reduce consumption of 
ethanol in animal models [7,8] and in humans [9,10]. Drugs that either enhance or diminish 
serotonergic function have been tried in both animal models and clinical trials with varying degrees of 
success [11–13] that may be due to differences in response by different sub-types of alcohol-dependent 
subjects [14]. 
In addition to the acceptor site for glutamate itself, the glutamate NMDA receptor has several 
different binding sites that can be targeted to modify the functioning of the receptor. Drugs that target 
this receptor to reduce glutamate activation will reduce the volitional consumption of ethanol by 
selectively bred high ethanol preferring rats. Thus, a drug that directly inhibits the binding of 
glutamate to this ligand-operated channel, LY 274614 (3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]-
decahydroisoquinoline-3-carboxylic acid), drugs that inhibit the binding of glycine to an accessory site 
on the receptor, (+)-HA-966 (3-amino-1-hydroxy-2-pyrrolidone) and ACPC (1-aminocyclo-propane-1-
carboxylic acid), a drug that binds to the “PCP-site” to potently and non-competitively inhibit, 
dizolcipine (MK-801), or a drug that blocks the opened channel, memantine, all will decrease 
volitional consumption at doses with insignificant or small effects on food intake and motor 
performance [15,16]. In humans, pre-treatment of moderate drinkers with memantine reduced the 
craving for alcohol prior to their receiving alcohol, but not afterwards [17,18]. However, memantine 
did not alter drinking patterns of moderate drinkers (6–8 drinks per day) who met DSM-IV criteria for 
alcohol-dependence [19]. The subjects in this latter study did not appear to meet the description for 
type 2 early onset heavy drinkers [20,21]. 
The glutamate NMDA receptor is a ligand-operated Ca
2+
 channel. When the neuronal membrane 
becomes less polarized, the activation of the NMDA receptor by glutamate will allow Ca
2+
 to flow into 
the cell until repolarization allows Mg
2+
 move back into the channel. The influx of Ca
2+
 will contribute 
to an excitatory postsynaptic potential that makes the neuron more likely to discharge and the Ca
2+
 will 
interact with intracellular proteins. One such calcium-activated enzyme is Ca
2+
-/calmodulin-dependent 
phosphatase, calcineurin. In dopaminergic-responsive neurons, this enzyme will remove a phosphate 
from DARPP-32 (dopamine and cAMP-regulated phosphoprotein of Mr 32 kDa) at Thr34 and 
decrease its activity. The activation of dopamine D1 receptors increases the production of cAMP, in 
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turn activating PKA, which puts a phosphate on DARPP-32 at Thr34 and activate the enzyme. NMDA 
agonists will decrease the activation of DARPP-32 due to Ca
2+
 activation of calcineurin [22]. This 
raises the interesting hypothesis that if memantine could reduce the activity of calcineurin by 
decreasing the intracellular levels of Ca
2+
, DARPP-32 would remain activated longer, and there may 
be an additive or possibly a synergistic action between a D1 agonist and this inhibitor of the NMDA 
receptor. The following experiments test this hypothesis through the use of the selectively bred Myers’ 
high ethanol preferring (mHEP) rat [23] that voluntarily consumes large amounts of ethanol solutions 
and injections of varying doses of a D1 partial agonist, SKF 38393 [(±)-1-phenyl-2,3,4,5-tetrahydro-
(1H)-3-benzazepine-7,8-diol] and either memantine or (+)MK-801, both non-competitive inhibitors of 
the glutamate NMDA receptor [24]. 
2. Experimental 
Animals: The Myers mHEP rats were selectively bred and maintained in the vivarium at East 
Carolina University under a 12-hour lights on/off schedule. The progenitors for this line were three 
alcohol preferring (P) rats purchased from Indiana University by R. D. Myers and bred with female  
Sprague-Dawley rats [23] and are known to have low concentrations of serotonin in several brain  
areas [25]. All procedures were approved by the Institutional Animal Care and Use Committee and 
were in compliance with the NIH Guide for the Care and Use of Laboratory Animals. 
Procedures: Male rats from the F31–F34 generations were moved to cages with three drinking 
tubes mounted on the front, one contained tap water, one contained ethanol in tap water and one was 
left empty, and the positions rotated in a semi-random order daily. Rats were first subjected to a  
10-day step-up procedure [23] with the ethanol concentration increased each day from 3% to 30%. 
Body weight and the consumption of food and fluids were measured daily. The concentration of 
ethanol for each rat that resulted in the greatest amount of ethanol consumed with a proportion of 
ethanol solution to total fluids consumed closest to 50% was then used as that rat’s preferred 
concentration for the remaining experiments. 
In order to test the effects of drug combinations on consumatory behavior: a group of rats were 
divided into two sub-groups in order to make drug and vehicle injections in a counter-balanced design. 
For each treatment cycle there would be a 3-day pre-treatment period, followed by 3-days of injections 
made at 2 hours before and 2 hours after lights out and then a 3-day post-treatment period. After 
drinking returned to baseline levels, each rat was put through the cycle again. Injections consisted of 
vehicles for both SKF 38393 and memantine (Veh/Veh); the vehicle for SKF 38393 and a dose of 
memantine injected i.p. (Veh/Mem); a dose of SKF 38393 injected s.c. and the vehicle for memantine 
(SKF/Veh); or doses of both drugs (SKF/Mem). Each rat served as its own control at one dose 
combination of SKF 38393 and memantine. An additional group of rats was used with SKF 38393 and 
(+)-MK 801 as the non-competitive NMDA receptor antagonist. Consumption was averaged for each 
of the three-day periods, then analyzed by repeated measures ANOVA and Tukey’s HSD test [26] with 
the aid of PRISM software. 
Drugs: SKF 38393, [(±)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol)·HCl], memantine 
hydrochloride and (+)-MK-801 hydrogen maleate were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Drugs were dissolved in distilled water and doses were calculated as the free base. Saline 
was used as the vehicle control for all drugs. 
Pharmaceuticals 2013, 6 472 
 
3. Results 
Table 1 shows the results from the interaction of 2.5 mg/kg s.c. SKF 38393 and 1.0 mg/kg i.p. 
memantine on the consumatory behavior of the mHEP rat. These doses were chosen as being minimal 
effective doses for a decrease in the consumption of ethanol [16,27]. As can be seen, there were small 
decreases in consumption with either drug alone, but no additivity when the drugs were combined, 
only a 17.3% decrease in the amount consumed compared to the pre-treatment baseline. In addition, 
proportion of ethanol to total fluid intake (or preference) did not change and there was a small decrease 
in food consumption. Body weight continued to increase in all four groups (data not shown). 
Table 1. Effects of 2.5 mg/kg SKF-38393, 1.0 mg/kg memantine, or in combination b.i.d. for 
three days on daily ethanol consumption, proportion of fluids consumed and food intake. 
A. Consumption--g ethanol/kg/day 
 Pre During Post 
Veh/Veh 5.78 ± 0.62 5.83 ± 0.63 6.33 ± 0.56 
Veh/Mem 6.34 ± 0.65 4.85 ± 0.67 * 5.63 ± 0.81 
Veh/SKF 6.99 ± 0.51 5.13 ± 0.61 * 5.73 ± 0.72 
Mem/SKF 5.84 ± 0.64 4.83 ± 0.51 * 6.23 ± 0.64 
B. Proportion--mL ethanol/mL total fluids 
 Pre During Post 
Veh/Veh 0.59 ± 0.04 0.60 ± 0.05 0.58 ± 0.04 
Veh/Mem 0.56 ± 0.04 0.61 ± 0.06 0.58 ± 0.05 
Veh/SKF 0.64 ± 0.03 0.65 ± 0.04 0.64 ± 0.06 
Mem/SKF 0.58 ± 0.04 0.57 ± 0.05 0.57 ± 0.05 
C. Consumption of Food--g food/day 
 Pre During Post 
Veh/Veh 20.2 ± 1.1 20.2 ± 1.1 20.9 ± 1.4 
Veh/Mem 21.8 ± 1.8 20.1 ± 1.2 20.3 ± 0.9 
Veh/SKF 21.6 ± 1.2 19.3 ± 1.1 * 20.2 ± 1.3 
Mem/SKF 20.5 ± 1.3 18.4 ± 0.8 * 20.8 ± 1.1 
Values are Mean ± Standard Error; * Different from pre-treatment baseline, p < 0.05 (Tukey’s HSD test), N = 9. 
At the dose of 5.0 mg/kg s.c. SKF-38393 there occurred a significant decrease from the pre-treatment 
period in the consumption of ethanol by 42.8% and the proportion declined by 31.1% (Table 2). Food 
intake did not change in contrast to the first experiment. Memantine at a dose of 3.0 mg/kg i.p. 
produced a decrease in consumption of 19.6%, but did not cause a significant decline in the preference. 
When the two drugs were combined there was a 37.7% decrease in the consumption of ethanol along 
with a significant decrease in the proportion, but neither value was different from SKF-38393 alone. In 
this experiment, there were no significant changes in food intake and the rats continued to add body 
weight throughout the injection sequences. 
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Table 2. Effects of 5.0 mg/kg SKF-38393, 3.0 mg/kg memantine, or in combination b.i.d. for 
three days on daily ethanol consumption, proportion of fluids consumed and food intake. 
A. Consumption--g ethanol/kg/day 
 Pre During Post 
Veh/Veh 7.91 ± 0.49 7.40 ± 0.36 7.99 ± 0.29 
Veh/Mem 7.70 ± 0.38 6.19 ± 0.57 * 7.13 ± 0.48 
SKF/Veh 7.63 ± 0.52 4.36 ± 0.51 * 7.82 ± 0.65 
Mem/SKF 7.38 ± 0.51 4.60 ± 0.40 * 7.50 ± 0.61 
B. Proportion--mL ethanol/mL total fluids 
 Pre During Post 
Veh/Veh 0.63 ± 0.03 0.67 ± 0.03 0.66 ± 0.02 
Veh/Mem 0.64 ± 0.03 0.59 ± 0.04 0.59 ± 0.03 
SKF/Veh 0.61 ± 0.02 0.42 ± 0.04 * 0.59 ± 0.04 
Mem/SKF 0.60 ± 0.03 0.50 ± 0.04 * 0.65 ± 0.03 
C. Consumption of Food--g food/day 
 Pre During Post 
Veh/Veh 20.4 ± 0.9 19.5 ± 0.9 19.7 ± 1.2 
Veh/Mem 20.0 ± 1.0 20.5 ± 1.1 20.6 ± 1.1 
SKF/Veh 21.3 ± 1.0 20.3 ± 0.9 20.9 ± 0.9 
Mem/SKF 19.6 ± 1.1 19.4 ± 0.9 20.3 ± 1.0 
Values are Mean ± Standard Error; * Different from pre-treatment baseline, p < 0.05 (Tukey’s HSD test), N = 11. 
Table 3 shows the effects of 5.0 mg/kg s.c. SKF 38393 and 10 mg/kg i.p. memantine, doses 
previously demonstrated as being effective doses for a decrease in the consumption of ethanol. There 
were significant decreases in consumption with either drug alone: 27% with SKF and 40% with 
memantine; but no additivity when the drugs were combined, a 47% decrease in the amount consumed 
that is similar to memantine alone. However, the proportion of ethanol to total fluid intake  
(or preference) decreased only with the drug combination, but there was a robust decrease in food 
consumption with memantine alone (23.1%) or in combination with SKF 38393 (33.3%). This dose of 
memantine was producing an anti-caloric or other non-specific effect in these animals. Body weight 
was maintained or increased in all four groups. 
In Table 4, a dose of SKF 38393 that has been at threshold for significant effects on drinking was 
combined with a dose of (+)-MK-801 predicted to also be effective on reducing consumption of 
ethanol based on experience with the racemic mixture [16]. After the dose of 2.5 mg/kg s.c.  
SKF-38393 there occurred a significant decrease in the consumption of ethanol by 34% and the 
proportion declined by 19% compared to the pre-treatment period, both slightly higher than shown in 
Table 1 with rats from an earlier generation. MK-801 at a dose of 0.1 mg/kg i.p. produced a decrease 
in consumption of 32% from the pre-treatment period, but did not cause a significant decline in the 
preference. When the two drugs were combined there was a 21% decrease in the consumption of 
ethanol along with a significant decrease in the proportion, but neither value was different from  
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SKF-38393 alone. In this experiment, there were small changes in food intake and the rats continued to 
add body weight throughout the injection sequences. 
Table 3. Effects of 5.0 mg/kg SKF-38393, 10 mg/kg memantine, or in combination b.i.d. for 
three days on daily ethanol consumption, proportion of fluids consumed and food intake. 
A. Consumption--g ethanol/kg/day 
 Pre During Post 
Veh/Veh 6.55 ± 0.40 6.30 ± 0.33 6.18 ± 0.35 
Veh/Mem 6.23 ± 0.44 3.75 ± 0.54 *
#
 5.87 ± 0.61 
SKF/Veh 6.31 ± 0.35 4.59 ± 0.31 *
#
 6.02 ± 0.55 
Mem/SKF 6.27 ± 0.52 3.25 ± 0.51 *
#
 6.08 ± 0.56 
B. Proportion--mL ethanol/mL total fluids 
 Pre During Post 
Veh/Veh 0.72 ± 0.03 0.74 ± 0.03 0.66 ± 0.03 
Veh/Mem 0.66 ± 0.03 0.64 ± 0.05 0.65 ± 0.03 
SKF/Veh 0.71 ± 0.02 0.63 ± 0.03 0.69 ± 0.04 
Mem/SKF 0.65 ± 0.02 0.54 ± 0.05 *
#
 0.70 ± 0.03 
C. Consumption of Food--g food/day 
 Pre During Post 
Veh/Veh 21.5 ± 0.9 19.5 ± 0.9 * 20.4 ± 0.8 
Veh/Mem 21.0 ± 0.7 15.0 ± 1.1 *
#
 19.1 ± 0.6 
SKF/Veh 21.3 ± 0.9 19.7 ± 0.7 * 21.4 ± 1.0 
Mem/SKF 20.5 ± 0.5 13.0 ± 0.9 *
#
 20.7 ± 0.9 
Values are Mean ± Standard Error; *Different from pre-treatment baseline, # different from Veh/Veh,  
p < 0.05 (Tukey’s HSD test), N = 9. 
4. Discussion 
Ethanol has the effect of causing the dopaminergic neurons in the mid-brain to discharge at 
increased rates and the effect is mediated through opiate receptors [1] and ethanol increases 
extracellular concentrations of dopamine [28]. The hypothesis is that metabolism of monoamines by 
monoamine oxidase provides hydrogen peroxide equivalents for catalase to oxidize ethanol to 
acetaldehyde which then condenses with monoamines to form morphine-like compounds [29,30]. 
Stimulation of D1 receptors (25 µm SKF 38393) will increase production of cAMP, increase PKA 
activity, and activate DARPP-32. In turn, the NMDA receptor will become more phosphorylated and 
less sensitive to inactivation by ethanol [31]. Elimination of expression of either the D1 receptor or 
DARPP-32 in mice reduces ethanol-seeking behaviors [32,33]. In very large doses, amphetamines are 
neurotoxic to the dopaminergic neurons and these neurons can be protected by the NMDA receptor 
antagonist, MK-801 [34], a result that suggests important interactions between dopamine and 
glutamate in vivo. 
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Table 4. Effects of 2.5 mg/kg SKF-38393, 0.1 mg/kg (+)-MK-801 or in combination b.i.d. for 
three days on daily ethanol consumption, proportion of fluids consumed and food intake. 
A. Consumption--g ethanol/kg/day 
 Pre During Post 
Veh/Veh 5.88 ± 0.36 5.51 ± 0.28 5.40 ± 0.22 
Veh/Mem 5.80 ± 0.16 3.93 ± 0.25 *
#
 4.42 ± 0.23 * 
SKF/Veh 5.78 ± 0.28 3.82 ± 0.40 *
#
 5.82 ± 0.25 
Mem/SKF 4.92 ± 0.32 3.89 ± 0.19 *
#
 5.22 ± 0.25 
B. Proportion--mL ethanol/mL total fluids 
 Pre During Post 
Veh/Veh 0.66 ± 0.04 0.65 ± 0.04 0.59 ± 0.04 * 
Veh/Mem 0.65 ± 0.03 0.57 ± 0.05 * 0.53 ± 0.03 * 
SKF/Veh 0.64 ± 0.03 0.52 ± 0.05 *
#
 0.66 ± 0.04 
Mem/SKF 0.57 ± 0.03 0.54 ± 0.03 
#
 0.62 ± 0.04 
C. Consumption of Food--g food/day 
 Pre During Post 
Veh/Veh 20.6 ± 0.7 20.2 ± 0.7 20.9 ± 0.7 
Veh/Mem 21.6 ± 0.9 22.0 ± 1.2 22.4 ± 0.8 
SKF/Veh 21.0 ± 0.6 19.6 ± 0.7 * 21.6 ± 0.7 
Mem/SKF 22.3 ± 0.9 20.2 ± 0.9 * 20.7 ± 0.8 
Values are Mean ± Standard Error; * Different from pre-treatment baseline, # different from Veh/Veh,  
p < 0.05 (Tukey’s HSD test), N = 10. 
Stimulation of the D1 receptor will reduce consumption of ethanol in a limited access paradigm [35] 
and during operant responding for ethanol [36]. Systemic injection of either a D1 receptor agonist, 
SKF  38393, or a D1 receptor antagonist, SCH 23390, will reduce volitional consumption of ethanol by 
the mHEP rat [27]. That both an agonist and an antagonist at the D1 receptor reduce drinking suggests 
that deviation in either direction from normal dopaminergic function reduces the rewarding action of 
ethanol. SKF 38393 is a partial agonist at the D1 receptor and produces different behavioral effects as 
the dose is increased, but hyperactivity is not one [37]. When used as the stimulus in a drug 
discrimination paradigm, rats can detect SKF 38393 at the doses used in this study [38] and these 
doses will enhance locomotion induced by a D2 agonist [39]. If ethanol is thought of as an indirect DA 
agonist through enhanced release of DA, then the use of another agonist to reduce consumption is a 
standard ploy of addiction treatment. 
The hypothesis that a D1 receptor agonist and an NMDA receptor antagonist should add or 
synergize to reduce the consumption of ethanol was based on the report by Nishi and co-workers [22]. 
A D1 receptor agonist will activate DARPP-32 through the cAMP/PKA pathway and a NMDA agonist 
will counter the effect due to increased intracellular Ca
2+
 and activation of calcineurin. Their work 
suggests that a NMDA receptor antagonist would either further increase activated DARPP-32 or allow 
the enzyme to remain in the activated phosphorylated state. Doses of a D1 receptor agonist and NMDA 
antagonist were used that previously were demonstrated to decrease volitional consumption of ethanol 
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with minimal reductions in food intake or locomotor disruption. Contrary to the hypothesis, there was 
neither an additive nor synergistic interaction when such drugs were combined. Neither memantine nor 
MK-801 combined with SKF 38393 caused a decrease of the consumption of ethanol than that seen 
with the D1 agonist alone. Table 5 summarizes the percent decrease in consumption from the 3-day 
vehicle/vehicle treatment period produced by the different drugs and combinations. A dose-related 
inhibition by both memantine and SKF 38393 are evident, but no additivity or synergy when the drugs 
are combined. 
Table 5. Summary of data from the Tables 1–4. Percent decrease in the consumption 
(g/kg/day) of ethanol during treatment with SKF 38393 and either memantine or (+)-MK-801 
compared to the value during vehicle treatment are shown. 
 Vehicle 1.0 Mem 3.0 Mem 10 Mem 0.1 MK 
Vehicle -- 16.8% 16.4% 40.5% 28.7% 
2.5 SKF (Tbl 1) 
               (Tbl 4) 
12.0% 
30.7% 
17.3% 
-- 
-- 
-- 
-- 
-- 
-- 
29.4% 
5.0 SKF (Tbl 2) 
              (Tbl 3) 
41.1% 
37.1% 
-- 
-- 
37.8% 
-- 
-- 
48.4% 
-- 
-- 
One explanation for the failure is that the shift in phosphorylation of DARPP-32 at Thre34 has  
no influence on the consumption of ethanol. It would be necessary to measure total and threo-34  
phospho-DARPP-32 by western blot to determine whether changes in phosphorylation are occurring as 
predicted from in vitro studies. However, normally ethanol-seeking mice with DARPP-32 knocked out 
do not seek ethanol [33]. The C57bl mouse consumes ethanol largely for the calories [40], whereas the 
mHEP rat apparently consumes for a pharmacological effect [23]. It is possible that the signaling 
through the DARPP-32 phosphoprotein cascade is not related to the rewarding effect of ethanol in the 
mHEP rat. Also, an increase in intracellular Ca
2+
 will alter the activity of many enzymes in addition to 
calcineurin and the effects in a DARPP-32 expressing neuron will be different than in a neuron that 
does not. 
Another possible explanation is that memantine is too weak of an inhibitor of the NMDA glutamate 
receptor and perhaps is insufficient to reduce the calcium influx and activation of calcineurin (PP-2B). 
However, MK-801 is a more potent inhibitor of this receptor, but had no better effect when combined 
with SKF 38393. Or, it could be a matter of dosing. The doses of memantine and MK-801 were chosen 
based on prior work to have minimal motor and food consumatory effects. Large doses of these drugs 
produce an abnormal locomotor behavior, different from amphetamine-like stimulants (personal 
observation) and in the case of MK-801 in extreme can produce a ketamine-like dissociative anesthetic 
state. The goal was to avoid these extreme effects and in order to demonstrate synergy, threshold 
effective doses should combine to produce a strong effect on consumption. Simply, this was not seen. 
Finally, it may be possible that with the in vivo situation other sources of calcium are available to 
activate calcineurin so that de-phosphorylation of DARPP-32 still occurs. That is, the amount of 
calcium entry associated with the NMDAR is small compared to other sources of calcium within the 
cell. The hypothesis was based on the results obtained in vitro by the application of drugs to striatal 
tissue slices [22] and may not apply to the whole animal system or the concentrations of memantine 
and MK-801 from injection do not approach the degree of inhibition obtained in the slice preparations. 
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An alternative hypothesis is simply that these drugs reduce the activation of dopaminergic neurons by 
glutamate and reduce the amount of dopamine released in reward areas such as the nucleus accumbens 
and medial pre-frontal cortex. More research needs to be done to determine the mechanism of 
interaction of NMDA receptor drugs with ethanol on dopaminergic activity and dopamine release. 
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